Tobin Schilke Revance Therapeutics, Inc. (RVNC) insider trading activity

Tobin Schilke is CFO of Revance Therapeutics, Inc.. Currently has a direct ownership of 0 shares of RVNC, which is worth approximately $0. The most recent transaction as insider was on Jan 20, 2023, when has been sold 1,000 shares (Common Stock) at a price of $31.0 per share, resulting in proceeds of $31,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Tobin Schilke Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 20 2023	SELL Open market or private sale	$31,000 $31.0 p/Share	1,000 Reduced 1.7%	57,877 Common Stock
Jan 09 2023	SELL Open market or private sale	$102,406 $27.67 p/Share	3,701 Reduced 5.91%	58,877 Common Stock
Dec 31 2022	BUY Grant, award, or other acquisition	$7,856 $12.18 p/Share	645 Added 1.02%	62,578 Common Stock
Dec 15 2022	SELL Payment of exercise price or tax liability	$33,475 $21.5 p/Share	1,557 Reduced 2.45%	61,933 Common Stock
Sep 22 2022	BUY Grant, award, or other acquisition	-	42,349 Added 31.58%	91,739 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$11,339 $11.75 p/Share	965 Added 1.5%	63,490 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$41,165 $15.79 p/Share	2,607 Reduced 4.0%	62,525 Common Stock
Feb 15 2022	SELL Payment of exercise price or tax liability	$39,035 $13.35 p/Share	2,924 Reduced 4.3%	65,132 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	42,349 Added 28.66%	105,430 Common Stock
Dec 31 2021	BUY Other acquisition or disposition	$5,603 $13.87 p/Share	404 Added 0.59%	68,056 Common Stock
Dec 15 2021	SELL Payment of exercise price or tax liability	$24,772 $15.92 p/Share	1,556 Reduced 2.25%	67,652 Common Stock
Jun 30 2021	BUY Other acquisition or disposition	$10,744 $24.09 p/Share	446 Added 0.64%	69,208 Common Stock
Feb 15 2021	SELL Payment of exercise price or tax liability	$76,973 $28.97 p/Share	2,657 Reduced 3.72%	68,762 Common Stock
Feb 02 2021	BUY Grant, award, or other acquisition	-	22,620 Added 24.05%	71,419 Common Stock
Dec 31 2020	BUY Other acquisition or disposition	$10,530 $21.36 p/Share	493 Added 1.0%	48,799 Common Stock
Dec 15 2020	SELL Payment of exercise price or tax liability	$41,623 $26.75 p/Share	1,556 Reduced 3.12%	48,306 Common Stock
Sep 30 2020	SELL Payment of exercise price or tax liability	$136,912 $25.14 p/Share	5,446 Reduced 9.85%	49,862 Common Stock
Sep 30 2020	BUY Grant, award, or other acquisition	-	15,750 Added 22.16%	55,308 Common Stock

Also insider at

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare

Chief Financial Officer

Tobin Schilke

CFO

Nashville, TN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Value

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC

Account